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Resveratrol induces mitochondrial biogenesis and
protects against metabolic decline, but whether
SIRT1 mediates these benefits is the subject of
debate. To circumvent the developmental defects
of germline SIRT1 knockouts, we have developed
an inducible system that permits whole-body
deletion of SIRT1 in adult mice. Mice treated with
a moderate dose of resveratrol showed increased
mitochondrial biogenesis and function, AMPK acti-
vation, and increased NAD+ levels in skeletal muscle,
whereas SIRT1 knockouts displayed none of these
benefits. A mouse overexpressing SIRT1 mimicked
these effects. A high dose of resveratrol activated
AMPK in a SIRT1-independent manner, demon-
strating that resveratrol dosage is a critical factor.
Importantly, at both doses of resveratrol no improve-
ments in mitochondrial function were observed in
animals lacking SIRT1. Together these data indicate
that SIRT1 plays an essential role in the ability of
moderate doses of resveratrol to stimulate AMPK
and improve mitochondrial function both in vitro
and in vivo.
INTRODUCTION
Themammalian sirtuins (SIRT1–SIRT7) are a conserved family of
NAD+-dependent deacetylases and ADP-ribosyltransferasesCinvolved in numerous fundamental cellular processes including
gene silencing, DNA repair, and metabolic regulation (Baur
et al., 2010; Donmez and Guarente, 2010; Haigis and Sinclair,
2010). Deletion of SIRT1 in outbred strains of mice abrogates
the effect of caloric restriction (CR) on physical activity (Chen
et al., 2005) and life span extension (Boily et al., 2008), whereas
overexpression of SIRT1 mimics many of the salutary effects of
CR, including a reduced incidence of cardiovascular and meta-
bolic diseases (Banks et al., 2008; Bordone et al., 2007; Pfluger
et al., 2008), cancer (Herranz et al., 2010; Oberdoerffer et al.,
2008), and neurodegeneration (Donmez et al., 2010; Qin et al.,
2006). Recent human genetic studies also support a role for
SIRT1 in maintaining human health status with age (Dong
et al., 2011; Rutanen et al., 2010).
The polyphenol resveratrol (2,3,40-trihydroxystilbene) first
attracted scientific attention when it was linked to the cardio-
vascular benefits of red wine and was subsequently found to
possess potent antitumor activity (Jang et al., 1997). In 2003, a
screen for small molecule activators of SIRT1 identified 21
different SIRT1-activating molecules, the most potent of which
was resveratrol (Howitz et al., 2003). In the majority of studies
to date, resveratrol has been found to increase life span in
Saccharomyces cerevisiae, Caenorhabditis elegans, and Dro-
sophila melanogaster in a sirtuin-dependent manner, although
the life span extension in yeast and flies, and the Sir2 depen-
dence in worms, has been challenged (Agarwal and Baur,
2011). In addition, resveratrol extends life and delays the onset
of age-related phenotypes in a short-lived species of fish (Valen-
zano et al., 2006).
In obese rodents, treatment with resveratrol produces a variety
of health benefits including improved metabolic and vascular
function, decreased hepatic steatosis, reduced inflammation,ell Metabolism 15, 675–690, May 2, 2012 ª2012 Elsevier Inc. 675
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Resveratrol Induces Mitochondria/AMPK via SIRT1greater endurance, and a gene expression pattern resembling
CR (Barger et al., 2008a, 2008b; Baur et al., 2006; Lagouge
et al., 2006; Pearson et al., 2008; Ramadori et al., 2009). Recent
clinical studies show that resveratrol also confers metabolic
benefits in humans (Brasnyo et al., 2011; Crandall et al., 2012).
Understanding how resveratrol exerts its effects is important,
not only for the potential insights into the biological causes of
age-related diseases, but also to allow the development of
more potent and specific molecules.
One of the most robust and reproducible effects of resveratrol
treatment is an increase in mitochondrial mass (Baur et al., 2006;
Lagouge et al., 2006). SIRT1 promotes mitochondrial biogenesis
through deacetylation and activation of PGC-1a (Gerhart-Hines
et al., 2007; Rodgers et al., 2005), a master regulator of mito-
chondrial biogenesis that coactivates the nuclear respiratory
factors (NRF-1 and NRF-2), which induce the transcription of
genes involved in mitochondrial biogenesis (Scarpulla, 2011).
PGC-1a is also activated by another important metabolic sensor,
the AMP-activated protein kinase (AMPK) (Jager et al., 2007).
Though the effects of resveratrol and SIRT1 on PGC-1a are
well established, there is considerable debate about the mecha-
nism by which this regulation is achieved. One school of thought
is that the direct activation of SIRT1 by resveratrol is an in vitro
artifact (Beher et al., 2009; Borra et al., 2005; Kaeberlein et al.,
2005; Pacholec et al., 2010) and that resveratrol works primarily
by activating AMPK (Canto et al., 2009), potentially by inhibition
of phospodiesterases (PDEs), ATPase, or complex III (Gledhill
et al., 2007; Hawley et al., 2010; Park et al., 2012; Zini et al.,
1999). It has been proposed that AMPK then activates SIRT1
indirectly by elevating intracellular levels of its cosubstrate,
NAD+ (Canto et al., 2009; Fulco et al., 2008). Alternatively, resver-
atrol may first activate SIRT1 in vivo, leading to AMPK activation
via deacetylation and activation of the AMPK kinase LKB1 (Hou
et al., 2008; Ivanov et al., 2008; Lan et al., 2008).
Unfortunately, studies to date have been unable to determine
whichmodel is most relevant under physiological conditions. We
and others have shown that resveratrol activates AMPK in cell
culture and in vivo (Baur et al., 2006; Dasgupta and Milbrandt,
2007), and a study of AMPK knockout mice established that
AMPK is required for many of the beneficial effects of resveratrol
onmetabolic function (Umet al., 2010). On the other hand, recent
enzymological studies have presented evidence for direct SIRT1
activation by small molecules (Dai et al., 2010), and there is
a growing literature of cell culture studies in which the effects
of resveratrol are lost after knocking down or inhibiting SIRT1
(Breen et al., 2008; Csiszar et al., 2009; Fischer-Posovszky
et al., 2010; Gracia-Sancho et al., 2010; He et al., 2010; Ivanov
et al., 2008; Kao et al., 2010; Kim et al., 2011; Li et al., 2010;
Lin et al., 2010; Ohguchi et al., 2010; Park et al., 2010; Shindler
et al., 2010; Sulaiman et al., 2010; Tanno et al., 2010; Ungvari
et al., 2009; Vetterli et al., 2011; Xia et al., 2011; Yang et al.,
2010; Yoshizaki et al., 2010). Moreover, resveratrol’s central
effects on liver gluconeogenesis (Ramadori et al., 2009) are abro-
gated when SIRT1 activity is impaired in the hypothalamus
(Knight et al., 2011), and treatment of mice with a SIRT1 activator
that is structurally unrelated to resveratrol, SRT1720, increases
mitochondrial capacity in skeletal muscle (Feige et al., 2008)
and liver in a SIRT1-dependent manner (Minor et al., 2011), while
improving the health and survival of mice on a high-fat diet,676 Cell Metabolism 15, 675–690, May 2, 2012 ª2012 Elsevier Inc.similar to what has been observed with resveratrol (Minor
et al., 2011).
This study was aimed at testing whether the ability of resvera-
trol to activate AMPK and increase mitochondrial function
requires SIRT1 in vivo, and whether SIRT1 overexpression is
sufficient to mimic these effects. The main impediment to
studying SIRT1 in vivo has been the poor survival, impaired
growth, and developmental defects of germline SIRT1 knockout
mice (Cheng et al., 2003; McBurney et al., 2003; Sequeira et al.,
2008). While studies performed in outbred mice suggest that the
effects of resveratrol treatment on cancer may be impaired in
SIRT1 knockout mice (Boily et al., 2008, 2009), the knockout
mice used in these studies were small, sterile, and suffered
from craniofacial abnormalities and eyelid inflammatory condi-
tions, making interpretation of the data extremely difficult. To
circumvent these issues, we have developed an adult-inducible
SIRT1 knockout mouse. This mouse shows efficient deletion of
SIRT1 across a variety of tissues and appears grossly normal
and healthy beyond 1 year of age. Using these animals, as well
as cell culture models, we observe that the stimulation of
AMPK activity and increase in NAD+ levels, mitochondrial
biogenesis, and mitochondrial function in skeletal muscle by
a moderate dose of resveratrol are entirely dependent upon
SIRT1. Further, overexpression of SIRT1 mimics the effects of
resveratrol on both mitochondria and AMPK activation. Interest-
ingly, an 10-fold higher dose of resveratrol activates AMPK in
a SIRT1-independent manner, though improvements in mito-
chondrial function are SIRT1 dependent. Taken together, these
data highlight the differences resveratrol treatment can have at
different doses and demonstrate an important role for SIRT1 in
activating AMPK and mediating the benefits of resveratrol
in vivo.
RESULTS
Resveratrol Improves Mitochondrial Function and
Increases Mitochondrial Biogenesis in a SIRT1-
Dependent Manner
While both overexpression of SIRT1 and treatment with resvera-
trol have been shown to increase mitochondrial content via acti-
vation of PGC-1a, it remains to be established whether SIRT1 is
required for resveratrol to improvemitochondrial function in skel-
etal muscle. Our initial investigation was performed using C2C12
myoblasts, a murine skeletal muscle cell line. Following treat-
ment with 25 mM resveratrol, C2C12 cells showed a significant
increase in mitochondrial membrane potential (Figure 1A) and
cellular ATP content (Figure 1B). Treatment with the SIRT1 inhib-
itor EX-527 or shRNA knockdown of SIRT1 consistently reduced
mitochondrial membrane potential and ATP content and com-
pletely abolished the ability of resveratrol to improve these
parameters (Figures 1A–1E).
Further analysis revealed that resveratrol treatment increased
mtDNA copy number in control cells (Figure 1F and 1G), suggest-
ing that increased mitochondrial biogenesis may underlie the
ability of resveratrol to improve mitochondrial function. Similar
to the results with mitochondrial membrane potential and ATP,
knockdown of SIRT1 or EX-527 treatment completely blocked
the ability of resveratrol to increase mtDNA copy number. Immu-
noprecipitation of the SIRT1 target PGC-1a showed a substantial
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Figure 1. Improved Mitochondrial Function and Increased Mitochondrial Biogenesis in Response to Resveratrol Treatment Require SIRT1
(A and B) (A) Mitochondrial membrane potential and (B) ATP content in C2C12 cells treated with 25 mM resveratrol and 10 mM EX-527 for 24 hr.
(C) Representative immunoblot for SIRT1 and tubulin in C2C12 cells infected with SIRT1 or nontargeting shRNA.
(D and E) (D) Mitochondrial membrane potential and (E) ATP content in C2C12 cells infected with SIRT1 or nontargeting shRNA and treated with 25 mM resveratrol
for 24 hr.
(F and G) (F) Mitochondrial DNA content analyzed by means of quantitative PCR in C2C12 cells treated with 10 mM EX-527 or (G) infected with SIRT1 or non-
targeting shRNA and treated with 25 mM resveratrol. Relative expression values were normalized to untreated cells.
(H) C2C12 cells infected with SIRT1 or nontargeting shRNA, and expressing Flag-HA-PGC-1a, were treated with resveratrol 25 mM for 24 hr, and PGC-1a
acetylation was tested in Flag immunoprecipitates. Total PGC-1a was evaluated on total extracts as input.
(I) PGC-1a, NRF-1, NDUFS8, SDHb, Uqcrc1, COX5b, and ATP5a1 mRNA were analyzed by means of quantitative RT-PCR in C2C12 cells infected with SIRT1 or
nontargeting shRNA after 24 hr treatment with 25 mM resveratrol. Relative expression values were normalized to untreated cells.
Values are expressed as mean ±SEM (*p < 0.05 versus DMSO).
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Resveratrol Induces Mitochondria/AMPK via SIRT1decrease in PGC-1a acetylation in resveratrol-treated cells,
consistent with previous reports (Baur et al., 2006; Lagouge
et al., 2006). Importantly, resveratrol treatment had no effect
on PGC-1a acetylation in cells lacking SIRT1 (Figure 1H). Consis-
tent with these findings, resveratrol treatment increased mRNA
expression of a number of genes downstream of PGC-1a, in-
cluding transcription factors responsible for stimulating mito-
chondrial biogenesis (NRF-1, NRF-2) and components of theCmitochondrial electron transport chain (NDUFS8, SDHb, Uqcrc1,
COX5b, ATP5a1). All of the increases in gene expression were
absent in cells treated with EX-527 or in which SIRT1 expression
was knocked down (Figure 1I, data not shown).
Generation of Adult-Inducible SIRT1 Knockout Mice
To test whether these findings were relevant in vivo, we gener-
ated an adult-inducible whole-body SIRT1 knockout mouseell Metabolism 15, 675–690, May 2, 2012 ª2012 Elsevier Inc. 677
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Figure 2. Generation of Adult-Inducible SIRT1 KO Mice Revealed that Ability of Resveratrol to Improve Mitochondrial Function Requires
SIRT1 In Vivo
(A) Schematic representation of induction of SIRT1 KO and treatment with the different diets.
(B) Representative immunoblot for SIRT1 and tubulin in skeletal muscle and heart of WT and SIRT1 KO mice.
(C) State 3 respiration of isolated mitochondria from skeletal muscle of WT and SIRT1 KO mice on experimental diets (n = 8) (*p < 0.05 versus WT SD, #p < 0.05
versus WT HFD).
(D) State 4 respiration of isolated mitochondria from skeletal muscle of WT and SIRT1 KO mice on experimental diets (n = 8).
(E) FCCP-induced respiration of isolated mitochondria from skeletal muscle of WT and SIRT1 KO mice on experimental diets (n = 8, *p < 0.05 versus WT SD,
#p < 0.05 versus WT HFD).
(F) Mitochondrial membrane potential of isolated mitochondria from skeletal muscle of WT and SIRT1 KO mice on experimental diets (n = 8, *p < 0.05 versus WT
SD, #p < 0.05 versus WT HFD).
(G) Cellular ATP content from gastrocnemius of WT and SIRT1 KOmice on experimental diets (n = 8, *p < 0.05 versusWT SD, #p < 0.05 versusWTHFD, +p < 0.05
versus WT HFD).
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Resveratrol Induces Mitochondria/AMPK via SIRT1designed to circumvent the developmental issues commonly
observed in germline SIRT1 knockouts. We backcrossed tamox-
ifen-inducible cre-ERT2 mice (Ruzankina et al., 2007) to C57BL/
6J and combined this with floxed SIRT1Dex4 mice (Cheng et al.,
2003). Tamoxifen treatment did not result in detectable liver
damage, as reflected by serum aminotransferase levels 7 or
30 days after the final dose (see Figures S1E–S1H online).
Following tamoxifen treatment, S1Dex4ERT2 and control mice678 Cell Metabolism 15, 675–690, May 2, 2012 ª2012 Elsevier Inc.were placed on one of four different diets: a standard diet (SD),
a high-fat diet (HF; 60% FDC), a high-fat diet supplemented
with 400 mg resveratrol/kg of food (HFLR), or a high-fat diet sup-
plemented with a high dose of 4 g resveratrol/kg of food (HFHR).
The former is a relatively low dose used in our laboratories’
previous studies, while the latter dose is similar to the concentra-
tions used by other groups (Lagouge et al., 2006) (Figure 2A).
Feeding of these diets resulted in an approximate daily dose of
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Figure 3. Resveratrol Induces a Shift toward More Oxidative Fibers in a SIRT1-Dependent Manner
(A and B) MyHCI, MyHCIIa, MyHCIIb, and MyHCIIx mRNA analyzed by quantitative RT-PCR in gastrocnemius (A) and soleus (B) of WT and SIRT1 KO mice on
experimental diets. Relative expression values were normalized to WT SD mice (n = 4, *p < 0.05 versus WT HFD, #p < 0.05 versus WT SD, +p < 0.05 versus
WT SD).
(C) Representative immunoblot for MyHCIIa, MyHCIIb, and tubulin in gastrocnemius of WT and SIRT1 KO mice on experimental diets.
(D) Representative MyHCIIa immunostaining in gastrocnemius of WT and SIRT1 KO mice on experimental diets.
Values are expressed as mean ±SEM.
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Resveratrol Induces Mitochondria/AMPK via SIRT125–30 mg/kg per day and 215–230 mg/kg of body weight per
day, respectively.
Deletion of the catalytic region of SIRT1 in S1DE4-ERT2 (SIRT1
KO) mice was evaluated by western blot analysis. Full-length
SIRT1 protein was nearly undetectable in skeletal and cardiac
muscle of SIRT1 KO mice (Figure 2B) and substantially reduced
(>85%) in all other tissues examined (Figure S1D). In contrast to
themuch smaller size and developmental abnormalities reported
for the germline knockouts (Boily et al., 2008, 2009), induction of
SIRT1 knockout in adult mice did not result in any overt pheno-
type (Figures S1A and S1B). Similarly, whole-body measure-
ments of various metabolic parameters did not reveal any
obvious differences between SIRT1 KO and WT mice, although
weight gain was slightly lower in KO mice fed the SD (Table S1).
Resveratrol Improves Mitochondrial Function in
Skeletal Muscle of WT Mice but Has No Effect on Adult-
Inducible SIRT1 KO Mice
The function of mitochondria isolated from skeletal muscle was
significantly impaired by feeding of a high-fat diet, while treat-
ment with both high and low doses of resveratrol prevented
these deleterious effects. At both low and high doses, resveratrol
produced substantial increases in ADP-induced respiration
(state 3), maximal respiration (FCCP-induced), mitochondrialCmembrane potential, and cellular ATP levels (Figures 2C–2G).
Strikingly, none of the significant increases in mitochondrial
function seen in the WT mice treated with resveratrol were
observed in SIRT1 KO mice (Figure 2C–2G). While the beneficial
effects of resveratrol were clearly evident in animals treated with
both doses of resveratrol, the variability between animals re-
ceiving the higher dose was considerably greater. For this
reason, the majority of our subsequent analyses focused on
the cohorts receiving the lower dose of resveratrol (i.e., 25–
30 mg/kg per day).
Treatmentwith Resveratrol Induces a SIRT1-Dependent
Shift toward More Oxidative Muscle Fibers
In addition to impairment in mitochondrial function, feeding of
a high-fat diet is known to cause an increased abundance of
glycolytic muscle fibers. Thus, we tested whether treatment
with resveratrol counteracted these changes and, if so, whether
SIRT1 was required. Gene expression analysis of myosin heavy-
chain genes from gastrocnemius muscle indicated that while the
number of type I muscle fibers was not altered by resveratrol, the
abundance of highly glycolytic fast twitch (type IIb) muscle fibers
was lower, and more oxidative fast twitch (type IIa and IIx)
fibers were more abundant in resveratrol-treated mice (Fig-
ure 3A), consistent with the findings of Lagouge et al. (2006).ell Metabolism 15, 675–690, May 2, 2012 ª2012 Elsevier Inc. 679
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Resveratrol Induces Mitochondria/AMPK via SIRT1Together, these changes indicate an overall shift toward more
oxidative fiber types in response to resveratrol treatment.
Interestingly, as with the measures of mitochondrial function,
these changes in muscle type were entirely dependent upon
SIRT1 (Figure 3A). The shift toward more oxidative fibers and
the SIRT1 dependence of these effects was not exclusive to
gastrocnemius, as similar gene expression changes were
observed in the soleus muscle as well (Figure 3B). This induction
of oxidative type II fibers in response to resveratrol treatment in
WT but not SIRT1 KO mice was confirmed by western blot and
histological analysis (Figure 3C and 3D). These data demonstrate
that the ability of resveratrol to induce a shift toward more oxida-
tive muscle fibers, improve mitochondrial function, and increase
cellular ATP requires SIRT1.
Stimulation of Mitochondrial Biogenesis in Skeletal
Muscle Requires Functional SIRT1
We next sought to understand more precisely the mechanisms
by which resveratrol increases mitochondrial function and ATP
production, and to investigate their relationship to SIRT1. Based
on previous work, we expected that resveratrol treatment would
increase mitochondrial biogenesis, and we hypothesized that
these effects would be dependent upon SIRT1. We first as-
sessed citrate synthase activity, a commonly used marker of
mitochondrial content. Consistent with the changes observed
in fiber type and mitochondrial function, the high-fat diet
decreased citrate synthase activity in the gastrocnemius of WT
mice, and resveratrol treatment completely prevented this
decrease. Similarly, mRNA levels of components of the mito-
chondrial ETC were increased by resveratrol treatment. Interest-
ingly, none of these effects were observed in SIRT1 KO mice
(Figures 4A and 4B).
Consistent with the results in C2C12 cells, the decrease in
mtDNA copy number in HFD mice was prevented by resveratrol
treatment in the gastrocnemius of WT mice, while the SIRT1 KO
mice showed no response to resveratrol treatment (Figure 4C).
Measurement and quantification of mitochondrial mass by elec-
tron microscopy showed that resveratrol treatment induced
an increase in mitochondrial area in WT but not in SIRT1 KO
mice (Figure 4D, Figure S2). Additionally, transcript levels of
PGC-1a, PGC-1b, and the mitochondrial transcription factors
TFAM and TFB2M were increased in resveratrol-treated mice
in a SIRT1-dependent manner (Figure 4E). Importantly, these
effects were not exclusive to gastrocnemius, as similar changes
in citrate synthase activity, mtDNA copy number, and the tran-
scription of both ETC components andmitochondrial biogenesis
factors were also seen in the soleus and cardiac tissue of WT
mice in response to resveratrol treatment but were absent in
SIRT1 KO mice (Figure S3). Overall, our findings from adult-
inducible SIRT1 KOmice demonstrate that resveratrol increases
mitochondrial biogenesis, induces a shift toward more oxidative
muscle fibers, and improves mitochondrial function in mice on
a high-fat diet, and that all of these beneficial effects require
SIRT1.
Overexpression of SIRT1 Mimics the Effects of
Resveratrol Treatment in Skeletal Muscle
These data are consistent with the hypothesis that resveratrol
acts via SIRT1 to increase mitochondrial function in vivo. This680 Cell Metabolism 15, 675–690, May 2, 2012 ª2012 Elsevier Inc.hypothesis also predicts that SIRT1 overexpression should be
sufficient to mimic the effects of resveratrol. To test this, we
generated a SIRT1 transgenic mouse (SIRT1-Tg) that constitu-
tively expresses high levels of SIRT1 in skeletal muscle and other
tissues (Figure 5A, Figure S4A). This mouse differs from previous
whole-body SIRT1 transgenics that overexpress SIRT1 either at
lower levels (1.5- to 2-fold) (Banks et al., 2008; Pfluger et al.,
2008) or predominately in brain and adipose tissue (Bordone
et al., 2007). Interestingly, despite the high levels of SIRT1 ex-
pression in multiple tissues (>53), there was no detectable
difference in overall appearance, body weight, or home cage
behavior.
In a striking recapitulation of the effects of resveratrol treat-
ment, mitochondria isolated from the skeletal muscle of the
SIRT1-Tg mice had significantly greater mitochondrial mem-
brane potential, state 3 respiration, and maximal respiration
(Figures 5B–5E). Additionally, mtDNA copy number (Figure 5F)
as well as mRNA levels of ETC components and regulators of
mitochondrial biogenesis that were induced by resveratrol treat-
ment were similarly upregulated in mice overexpressing SIRT1,
while those unaffected by resveratrol were also unchanged in
SIRT1-Tg mice (Figures 5G and 5H). Together these data show
that overexpression of SIRT1 in skeletal muscle is sufficient to
induce mitochondrial biogenesis and improve mitochondrial
function. When coupled with the SIRT1 KO data establishing
that SIRT1 is required for the beneficial effects of resveratrol,
these results provide strong evidence that the ability
of resveratrol to improve mitochondrial function in skeletal
muscle is due to SIRT1-mediated stimulation of mitochondrial
biogenesis.
Resveratrol Alters Metabolism in SIRT1 KO Livers but
Not Primary KO Hepatocytes
As resveratrol has previously been found to improve metabolic
function in mice on a high-fat diet (Baur et al., 2006; Lagouge
et al., 2006) and mitochondrial dysfunction is known to play an
important role in the development of glucose imbalance in dia-
betes (Lowell and Shulman, 2005), we sought to determine
whether the ability of resveratrol to improve glucose homeo-
stasis was lost in our inducible SIRT1 knockout mice. As ex-
pected, blood glucose levels were elevated in high-fat-diet-fed
mice under both fed and fasted conditions. Resveratrol treat-
ment partially prevented the increase in both fed and fasted
blood glucose levels induced by high-fat diet in both WT and
SIRT1 KO mice, suggesting that these effects are at least
partially independent of SIRT1 (Figures S5A and S5B). Similarly,
resveratrol-treated WT and SIRT1 KO mice performed better in
a glucose tolerance test (Figures S5D and S5E). As the liver is
known to play a key role in regulating glucose homeostasis
and resveratrol was previously shown to improve liver function
(Baur et al., 2006; Baur and Sinclair, 2006), we evaluated liver
metabolism in response to resveratrol treatment. Liver weight
and triglycerides were reduced in both WT and SIRT1 KO mice
(Figures S5C and S5F). Analysis of gene expression in the livers
of these mice revealed an overall shift toward utilization of fatty
acids (Figure S5G) and increased mitochondrial biogenesis (Fig-
ure S6D), which in many cases occurred in both WT and SIRT1
KO mice. Resveratrol-treated mice also showed a significant
increase in COX activity and cellular ATP levels in both WT and
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Figure 4. Resveratrol Improves Mitochondrial Biogenesis in Skeletal Muscle of WT but Not SIRT1 KO Mice
(A) Citrate synthase activity measured in gastrocnemius from WT and SIRT1 KO mice on experimental diets (n = 8) (*p < 0.05 versus WT SD, #p < 0.05 versus
SIRT1 KO SD, +p < 0.05 versus WT HFD).
(B) NDUFS8, SDHb, Uqcrc1, COX5b, and ATP5a1 mRNA analyzed by quantitative RT-PCR in gastrocnemius of WT and SIRT1 KO mice on experimental diets.
Relative expression values were normalized to WT SD mice (n = 4 experiments, *p < 0.05 versus WT HFD).
(C) Mitochondrial DNA content analyzed by quantitative PCR in gastrocnemius of WT and SIRT1 KOmice on experimental diets. Relative expression values were
normalized to WT SD mice (n = 8 experiments, *p < 0.05 versus WT SD, #p < 0.05 versus WT HFD).
(D) Electronic microscopy analysis of gastrocnemius from WT and SIRT1 KO mice on experimental diets and the respective mitochondrial area quantification
(n = 4) (*p < 0.05 versus WT HFD).
(E) PGC-1a, PGC-1b, NRF-1, NRF-2, TFAM, TFB1M, and TFB2MmRNA analyzed by means of quantitative RT-PCR in gastrocnemius of WT and SIRT1 KOmice
on experimental diets. Relative expression values were normalized to WT SD mice (n = 4, *p < 0.05 versus WT HFD, #p < 0.05 versus WT SD, +p < 0.05 versus
WT SD).
Values are expressed as mean ±SEM.
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Resveratrol Induces Mitochondria/AMPK via SIRT1SIRT1 KO mice, while citrate synthase activity was unaltered
(Figures S6A–S6C).
In contrast to the knockout mouse, treatment of primary hepa-
tocytes isolated from liver-specific SIRT1 KO (Alb-Cre; SIRT1DE4)
mice or in HepG2 cells demonstrated that the ability of re-
sveratrol (25 mM) to induce changes in gene expression, AMPK
activation, and mitochondrial function of hepatocytes is SIRT1
dependent (Figures S6H–S6L and Figure S7J). These data indi-
cate that the benefits of resveratrol on liver physiology in the
SIRT1 KO mice may be due to signaling from other tissues orCthe incomplete deletion of SIRT1 in the livers of these mice. As
further evidence of the important role signaling between tissues
can play, we have observed that overexpression of SIRT1 ex-
clusively in SF1 neurons is sufficient to induce expression of
genes involved in mitochondrial biogenesis in skeletal muscle
(Figure S6M).
SIRT1 Is Required for Activation of AMPK by Resveratrol
Given the complex interplay between SIRT1 and AMPK, it has
been difficult to untangle their roles in mediating the effects ofell Metabolism 15, 675–690, May 2, 2012 ª2012 Elsevier Inc. 681
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Figure 5. Mice Overexpressing SIRT1 Mimic the Effects of Resveratrol on Mitochondrial Function and Biogenesis
(A) Representative immunoblot for SIRT1 and tubulin in gastrocnemius of 6-month-old WT and SIRT1 Tg mice.
(B) State 3 respiration of isolated mitochondria from skeletal muscle of WT and SIRT1 Tg mice (n = 6).
(C) State 4 respiration of isolated mitochondria from skeletal muscle of WT and SIRT1 Tg mice (n = 6).
(D) FCCP-induced respiration of isolated mitochondria from skeletal muscle of WT and SIRT1 Tg mice (n = 6).
(E) Mitochondrial membrane potential of isolated mitochondria from skeletal muscle of WT and SIRT1 Tg mice (n = 6).
(F) Mitochondrial DNA content analyzed bymeans of quantitative PCR in skeletal muscle ofWT and SIRT1 Tgmice. Relative expression valueswere normalized to
WT mice (n = 6).
(G) NDUFS8, SDHb, Uqcrc1, COX5b, and ATP5a1 mRNA analyzed by quantitative RT-PCR in gastrocnemius of WT and SIRT1 Tg mice. Relative expression
values were normalized to WT mice (n = 6).
(H) PGC-1a, PGC-1b, NRF-1, NRF-2, TFAM, TFB1M, and TFB2MmRNA analyzed by quantitative RT-PCR in gastrocnemius of WT and SIRT1 Tg mice. Relative
expression values were normalized to WT mice (n = 6).
Values are expressed as mean ±SEM (*p < 0.05 versus WT).
Cell Metabolism
Resveratrol Induces Mitochondria/AMPK via SIRT1resveratrol, but the inducible SIRT1 KOmouse presented us with
an opportunity to test their epistasis. Our previous work showed
that resveratrol increases levels of activated (phosphorylated)
AMPK in vivo (Baur et al., 2006), indicating that AMPK may
play a role in mediating resveratrol’s benefits. This was sup-
ported by a subsequent study demonstrating that AMPK is
required for many of the metabolic effects of resveratrol in vivo
(Um et al., 2010). Consistent with this, the ability of resveratrol682 Cell Metabolism 15, 675–690, May 2, 2012 ª2012 Elsevier Inc.and SIRT1 overexpression to boost cellular ATP and mtDNA
copy number was prevented by knockdown of the AMPKa1
subunit or treatment with Compound C, an AMPK inhibitor
(Figures 6A–6E and Figures S7A–S7E).
Treatment with a moderate dose of resveratrol increased the
levels of phosphorylated AMPK and NAD+ in gastrocnemius of
WT mice (Figures 6F–6I). Strikingly, none of these changes were
observed in SIRT1 KO mice. Consistent with these findings, the
Cell Metabolism
Resveratrol Induces Mitochondria/AMPK via SIRT1regulation of AMPK-regulated genes involved in fatty acid
metabolism (LCAD, MCAD, CPT1b, FAS, and Scd1) was also
dependent upon SIRT1. Interestingly, at the higher dose of re-
sveratrol, many of these effects were SIRT1 independent,
demonstrating that the dose is critical to the outcome (Figures
6F and 6G, Figures S7F and S7G). SIRT1-overexpressing mice
had significantly increased levels of AMPK phosphorylation
(Figures 6J and 6K). Together these data demonstrate that
SIRT1 is necessary for moderate doses of resveratrol to activate
AMPK and increase NAD+ and that SIRT1 acts upstream of
AMPK. Interestingly, despite the different requirements for re-
sveratrol to activate AMPK in the SIRT1 KO mice, neither dose
of resveratrol improved mitochondrial function in the absence
of SIRT1 (Figure 2).
Resveratrol has been implicated in the direct modulation of
numerous targets (Baur and Sinclair, 2006), but it has been diffi-
cult to discern which of these targets are physiologically rele-
vant. Part of the difficulty has arisen from the fact that doses of
resveratrol given to animals are wildly variable and concentra-
tions used on cells vary greatly as well (Kim et al., 2007; Park
et al., 2012). To provide some clarity, we performed a series of
dose and time course experiments with resveratrol. Treatment
of C2C12 cells with a moderate dose of resveratrol (25 mM) acti-
vated AMPK in a SIRT1-dependent manner, while at a higher
dose of resveratrol (50 mM) AMPK was activated in a SIRT1-
independent manner (Figure 7A). Similarly, treatment with the
lower dose of resveratrol for 24 hr mimicked the effects on
muscle in vivo by increasing ATP and mitochondrial membrane
potential. In contrast, the 50 mM dose reduced mitochondrial
membrane potential and cellular ATP levels, indicative of mito-
chondrial dysfunction, an effect of resveratrol that was not
observed in vivo (Figures 7B and 7C).
Treatment with 25 mM resveratrol elevated ATP levels at 4, 6,
and 12 hr, consistent with what we observed in vivo (Figure 7D).
In contrast, the 50 mM dose significantly decreased ATP levels
early as 1 hr after treatment. At the 25 mM dose, activation
of AMPK occurred in a SIRT1-dependent manner, while the
50 mMdose activated AMPK independently of SIRT1 (Figure 7E).
Importantly, the increase in ATPwas evident before any changes
in cellular NAD+ levels were detected (Figure 7F), indicating that
improvements in mitochondrial function and elevation of cellular
ATP levels are both dependent upon SIRT1 and occur prior to
increases in cellular NAD+.
To further elucidate the epistasis of SIRT1 and AMPK, we
treated primary hepatocytes and myoblasts isolated from
SIRT1 KO mice with AICAR, an AMP mimetic that directly acti-
vates AMPK and promotes its phosphorylation by LKB1. Phos-
phorylation of AMPK by AICAR was blunted in both the primary
hepatocytes and primary myoblasts lacking SIRT1 (Figure 7G
and Figure S7J). Moreover, the ability of AICAR to increase mito-
chondrial DNA copy number and ATP in the liver and muscle KO
cells was completely blocked (Figures 7H and 7I and Figures
S7H and S7I). In further support of SIRT1 acting upstream of
AMPK, treatment of C2C12 cells with 25 mM resveratrol resulted
in a SIRT1-dependent decrease in LKB1 acetylation (Figure 7J).
These findings are consistent with previous work done in C2C12
cells (Canto et al., 2009) and support previous findings that
resveratrol-stimulated, SIRT1-mediated deacetylation of LKB1
plays a direct role in the activation of AMPK (Ivanov et al.,C2008; Lan et al., 2008). Taken together, these findings show
that treatment of mice on a high-fat diet with moderate doses
of resveratrol results in increased phosphorylation of AMPK,
induction of mitochondrial biogenesis, increased ATP and
NAD+ levels, and a shift toward more oxidative muscle fibers,
all of which are SIRT1-dependent effects.
DISCUSSION
Genetic disorders with impairedmitochondrial function are char-
acterized by a rapid onset of symptoms commonly seen in the
elderly, such as type II diabetes, muscle loss, and neurodegen-
eration (Finsterer, 2004; Sahin et al., 2011; Wallace, 2010). More-
over, there is increasing evidence that declining mitochondrial
function in normal individuals may underlie a number of common
age-related diseases (de Moura et al., 2010; Figueiredo et al.,
2009; Wallace, 2005) and that treatments that stimulate mito-
chondrial function can delay the progression of some of these
diseases (Baur et al., 2006; Fillmore et al., 2010; Horvath et al.,
2011; Hwang et al., 2009; Lagouge et al., 2006; Wenz et al.,
2009). Skeletal muscle is one of the primary tissues responsible
for insulin-stimulated glucose uptake, and reduced mitochon-
drial function has been shown to play an important role in the
development of insulin resistance with obesity (Morino et al.,
2006; Wallace, 2005). Therefore, stimulation of pathways up-
stream of mitochondrial biogenesis may prove effective in delay-
ing and treating a variety of rare and common diseases.
Treatment of rodents with resveratrol, SRT1720, or overex-
pression of SIRT1 has been shown to activate PGC-1a and
prevent diseases commonly associated with mitochondrial dys-
function and aging (Banks et al., 2008; Baur et al., 2006; Bordone
and Guarente, 2005; Herranz et al., 2010; Lagouge et al., 2006;
Pearson et al., 2008). Interestingly, skeletal muscle-restricted
overexpression of PGC-1a is sufficient to delay many age-
related phenotypes and extend mouse life span (Wenz et al.,
2009). In cell culture, many of the effects of resveratrol are no
longer observed in cells with impaired SIRT1 activity (Breen
et al., 2008; Csiszar et al., 2009; Fischer-Posovszky et al.,
2010; Gracia-Sancho et al., 2010; He et al., 2010; Ivanov et al.,
2008; Kao et al., 2010; Kim et al., 2011; Li et al., 2010;
Lin et al., 2010; Ohguchi et al., 2010; Park et al., 2010; Shindler
et al., 2010; Sulaiman et al., 2010; Tanno et al., 2010; Ungvari
et al., 2009; Vetterli et al., 2011; Xia et al., 2011; Yang et al.,
2010; Yoshizaki et al., 2010). However, the ability of resveratrol
to elicit cellular changes in a SIRT1-independent manner (Bjor-
klund et al., 2011; Centeno-Baez et al., 2011; Mader et al.,
2010; Zhang, 2006), and the dependency of resveratrol’s effects
on AMPK in vivo (Um et al., 2010), have fueled an active debate
about how resveratrol is able to mimic CR, protect against
a high-fat diet, and improve mitochondrial function in vivo.
The adult-inducible SIRT1 knockout mouse strain described
here has allowed us to directly assess the effects of resveratrol
treatment in otherwise healthy adult animals lacking functional
SIRT1. Using this model, we clearly demonstrate that the ability
of resveratrol to stimulate mitochondrial biogenesis, increase
mitochondrial function, and raise both ATP and NAD+ levels in
skeletal muscle is dependent on SIRT1 in vivo. While further
work is needed to fully determine the importance of SIRT1 in
the ability of resveratrol to prevent metabolic syndrome andell Metabolism 15, 675–690, May 2, 2012 ª2012 Elsevier Inc. 683
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Figure 6. Resveratrol Activates AMPK through SIRT1-Dependent and -Independent Mechanisms Depending on Dose
(A) Representative immunoblot for AMPKa and tubulin in C2C12 cells infected with AMPKa or nontargeting shRNA.
(B) ATP content in C2C12 cells infected with AMPKa or nontargeting shRNA and treated with 25 mM resveratrol for 24 hr (n = 5, *p < 0.05 versus DMSO).
(C) Mitochondrial DNA content analyzed by quantitative PCR in C2C12 cells infected with AMPKa or nontargeting shRNA and treated with 25 mM resveratrol for
24 hr. Relative expression values were normalized to WT (n = 5, *p < 0.05 versus DMSO).
(D) ATP content in C2C12 cells infected with AMPKa or nontargeting shRNA and treated with adenovirus overexpressing SIRT1 or empty vector (n = 5, *p < 0.05
versus empty DMSO).
(E) Mitochondrial DNA content analyzed by quantitative PCR in C2C12 cells infected with AMPKa or nontargeting shRNA and with adenovirus overexpressing
SIRT1 or empty vector. Relative expression values were normalized to control (n = 5, *p < 0.05 versus empty DMSO).
(F) Representative immunoblot for p-AMPK (Thr172) and total AMPK in gastrocnemius of WT and SIRT1 KO mice on experimental diets.
(G) Quantification of AMPK activity evaluated by the ratio of p-AMPK and AMPK in gastrocnemius of WT and SIRT1 KO mice on experimental diets (n = 8).
(H) AMP/ATP ratio in gastrocnemius of WT and SIRT1 KO mice on experimental diets (n = 4) (*p < 0.05 versus WT SD, #p < 0.05 versus WT HFLR).
(I) NAD+ content in gastrocnemius of WT and SIRT1 KO mice on experimental diets (n = 4, *p < 0.05 versus WT SD, #p < 0.05 versus WT HF, +p < 0.05 versus
SIRT1 KO HF).
(J) Representative immunoblot for p-AMPK (Thr172), and total AMPK in gastrocnemius of WT and SIRT1 Tg mice.
(K) Quantification of AMPK activity evaluated by the ratio of quantification of p-AMPK and AMPK in gastrocnemius of WT and SIRT1 Tg mice (n = 6, *p < 0.05
versus WT).
Values are expressed as mean ±SEM.
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Cell Metabolism
Resveratrol Induces Mitochondria/AMPK via SIRT1other age-related diseases, this study provides in vivo evidence
that beneficial effects of resveratrol on mitochondrial function
require SIRT1.
Given our observation that resveratrol increases the transcript
levels of PGC-1a, mitochondrial transcription factors, and
components of the electron transport chain, the beneficial
effects of resveratrol on skeletal muscle are likely due to PGC-
1a-mediated increases in mitochondrial biogenesis and a shift
toward more oxidative muscle fibers. Consistent with this, over-
expression of PGC-1awas recently reported to result in a similar
shift toward more oxidative fiber types (Rasbach et al., 2010).
This model is also consistent with the data from our SIRT1-Tg
mouse, which showed changes in mitochondrial biogenesis,
mitochondrial function, and cellular energy status similar to
those inmice treatedwith resveratrol. Thismouse further corrob-
orates the striking parallels between resveratrol treatment, CR,
and increased SIRT1 activity (Baur et al., 2006; Cohen et al.,
2004; Pearson et al., 2008; Smith et al., 2009).
SIRT1 and AMPK have been shown to play many similar roles,
including their ability to respond to stress and nutrient status,
inducemitochondrial biogenesis, regulate glucose homeostasis,
and control the activity of important transcriptional regulators
such as PGC-1a, FOXOs, and p300 (Fulco and Sartorelli,
2008). Similarly, the beneficial effects of both CR and resveratrol
have been suggested to involve activation of SIRT1 and AMPK
(Boily et al., 2008, 2009; Um et al., 2010). As such, it has been
difficult to untangle the epistasis of SIRT1 and AMPK. There is
clearly a dynamic interaction between these two pathways.
AMPK has been shown to activate SIRT1, likely through an indi-
rect increase in cellular NAD+ levels (Canto et al., 2009), while
SIRT1 deacetylates the AMPK kinase LKB1, leading to increased
phosphorylation and activation of AMPK (Ivanov et al., 2008; Lan
et al., 2008).
In light of the data generated using our adult-inducible SIRT1
KO mice, we can reassess the physiologic relevance of pro-
posed models of resveratrol’s action. If resveratrol induces
AMPK by acting as an ATPase or complex III inhibitor (Gledhill
et al., 2007; Hawley et al., 2010; Zini et al., 1999), then ATP levels
should be lower in the resveratrol-treated mice, and AMPK acti-
vation should occur independently of SIRT1. We do not observe
such effects using moderate doses of resveratrol in vitro or
in vivo. In time course cell culture experiments, ATP levels
were not altered after 1 hr and steadily increased at the 4, 6,
and 12 hr time points, while NAD+ levels were not significantly
increased until 12 hr of treatment. Moreover, we found no
evidence of a decrease in ATP or increase in AMP in animals
treated with either a low or high dose of resveratrol. Thus,
whenmoderate doses are used, it seems unlikely that resveratrol
activates AMPK by altering AMP and/or ATP levels. In contrast,
50 mM resveratrol caused a dramatic decline in mitochondrial
membrane potential and ATP levels. Thus, SIRT1-independent
activation of AMPK by high concentrations of resveratrol may
be secondary to inhibition of mitochondrial respiration and ATP
synthesis.
In a recent study, a newmodel was presented in which resver-
atrol increases mitochondrial biogenesis by inhibiting PDE,
leading to increased levels of cAMP. This increases cellular
calcium levels, thereby stimulating phosphorylation of AMPK
by CamKKb. As cellular NAD+ levels were found to be elevatedCunder these conditions, this was proposed as a mechanism by
which resveratrol activates SIRT1. This model is not consistent
with the effects we have observed with moderate doses of
resveratrol in vitro or in vivo, as increases in p-AMPK, NAD+,
LKB1 acetylation, and mitochondrial function were entirely
SIRT1 dependent. Inhibition of PDE may, however, provide an
explanation for some of the effects seen in animals treated
with a higher dose of resveratrol where phosphorylation of
AMPK and increased levels of NAD+ are observed independently
of SIRT1.
In experiments using pharmacological agents, it is well recog-
nized that care should be taken to use the lowest effective dose
to minimize the chances of off target effects. Our study exem-
plifies the risk of using high doses of resveratrol: we clearly
show that the ability of resveratrol treatment to increase phos-
phorylation of AMPK both in vivo and in vitro was dependent
upon SIRT1, but only at moderate doses. Moreover, treatment
of cells with low doses of resveratrol mimicked the in vivo situa-
tion, but high doses of resveratrol (R50 mM) resulted not only in
SIRT1-independent activation of AMPK but also in toxic effects
that included a dramatic reduction in mitochondrial membrane
potential and cellular ATP levels.
In this study we chose to test the SIRT1 dependence of resver-
atrol in cardiac and skeletal muscle, two organs with high ener-
getic demands requiring efficient mitochondrial function. Cell
culture experiments performed with hepatocytes from liver-
specific SIRT1 knockout mice demonstrated that SIRT1 is
required for resveratrol and AICAR to induce phosphorylation
of AMPK and increase mitochondrial biogenesis and function.
In the mouse, however, resveratrol improved glucose homeo-
stasis and liver function in both WT and SIRT1 KO mice. It
remains unclear whether the SIRT1-independent effects we
observed are due to an accumulation of resveratrol in specific
organs, the inefficiency of SIRT1 knockdown in liver, or differ-
ences in the actions of resveratrol between cell types. The
discrepancymay also be due to contributions from other tissues.
For example, direct administration of resveratrol to the brain of
rodents has been found to improve whole-body glucose homeo-
stasis (Ramadori et al., 2009), and these effects were lost when
SIRT1 function in the hypothalamus was impaired (Knight et al.,
2011). Additionally, overexpression of SIRT1 in SF1 neurons is
sufficient to induce the expression of genes involved in mito-
chondrial biogenesis in skeletal muscle, further demonstrating
the complex interplay between tissues.
Using adult-inducible SIRT1 knockout mice, we have been
able to test whether beneficial effects of resveratrol treatment on
musclemitochondrial function are dependent uponSIRT1 in vivo.
Our data clearly show that treatment with moderate doses
of resveratrol results in AMPK activation, induction of mitochon-
drial biogenesis, and improved mitochondrial function in
a manner that is dependent upon SIRT1. It is worth noting that
even when AMPK was induced in a SIRT1-independent manner
in vivo, the ability of high doses of resveratrol to improve
mitochondrial function still required SIRT1. We favor a model
whereby moderate doses of resveratrol first activate SIRT1,
which leads to deacetylation of LKB1 and activation of
AMPK (Figure 7K). Clearly, SIRT1 and AMPK do not function
independently or linearly. The subsequent increase in NAD+
levels likely contributes to a positive feedback cycle that mayell Metabolism 15, 675–690, May 2, 2012 ª2012 Elsevier Inc. 685
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(A) Representative immunoblot for p-AMPK (Thr172) and total AMPK in C2C12 cells infected with SIRT1 or nontargeting shRNA and treated with 10, 25, or 50 mM
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Cell Metabolism
Resveratrol Induces Mitochondria/AMPK via SIRT1
686 Cell Metabolism 15, 675–690, May 2, 2012 ª2012 Elsevier Inc.
Cell Metabolism
Resveratrol Induces Mitochondria/AMPK via SIRT1serve to sustain the effects of increased SIRT1 activity beyond
the activating stimulus. This model supports the enticing possi-
bility of designing and developing potent small molecules that
provide the health benefits of resveratrol by activating SIRT1
and downstream pathways to treat metabolic and other age-
related diseases.
EXPERIMENTAL PROCEDURES
Generation of aWhole-Body Adult-Inducible SIRT1 Knockout Mouse
Mice harboring a Cre-ERT2 fusion protein consisting of Cre recombinase
fused to a triple mutant form of the human estrogen receptor, which does
not bind its natural ligand (17b-estradiol) at physiological concentrations but
will bind the synthetic estrogen receptor ligands 4-hydroxytamoxifen (OHT)
and tamoxifen citrate have been described previously (Ruzankina and Brown,
2007). Cre-ERT2 is restricted to the cytoplasm and can only enter nuclear
compartment following treatment with tamoxifen. These mice were crossed
to SIRT1Dex4 mice (Cheng et al., 2003) to generate SIRT1Dex4ERT2 mice in
which the catalytic region of SIRT1 can be deleted upon treatment with
tamoxifen. Cre induction was carried out by 6 week feeding of a diet contain-
ing 360 mg/kg tamoxifen citrate to SIRT1Dex4ERT2 and control mice. Controls
included animals with a WT SIRT1 allele and ERT2 and SIRT1Dex4 mice lacking
ERT2. Following tamoxifen treatment, efficiency of deletion in DNA from tail
samples was determined by PCR (Figure S1C), and animals were maintained
on experimental diets for 8 months. Diets included AIN-93G SD, AIN-93G
modified to provide 60% of calories from fat (HF), or high-fat diet with the
addition of 0.04% resveratrol (HFLR) as previously described (Baur and
Sinclair, 2006) as well as a high-fat diet containing 0.4% resveratrol (HFHR).
All animal care followed the guidelines and was approved by the Institutional
Animal Care and Use Committees (IACUCs) at Harvard Medical School
(SIRT1-Tg and SIRT1-inducible KO), the University of Pennsylvania (Alb-Cre
SIRT1 KO), and the University of Texas Southwestern Medical Center
(SF1-specific SIRT1-Tg).
Generation of a Whole-Body SIRT1 Overexpressor Mouse
A Cre-inducible SIRT1 transgenic mice harboring a transcriptional STOP
element flanked with loxP sites inserted between a CAGGS promoter and
the murine SIRT1 cDNA was described previously (Firestein et al., 2008). To
generate constitutive SIRT1 transgenic animals (SIRT1-Tg), SIRT1STOP mice
were crossed with CMV-Cre transgenic mice strains obtained in the C57/
BL6J background from Jackson Labs (Bar Harbor, ME). SIRT1tg;CMV-Cre
double transgenics were then backcrossed to C57BL/6J to outcross the
CMV-Cre allele.
C2C12 Cell Culture Treatments, Adenoviral Infections, and SIRT1
Gene Silencing
Methods for cell culture treatments, adenoviral infections, and SIRT1 and
AMPKa gene silencing in C2C12 cells can be found in the Supplemental
Information.(B) ATP content in C2C12 cells treated with 25 or 50 mM resveratrol for 24 hr (n =
(C) Mitochondrial membrane potential in C2C12 cells treated with 25 or 50 mM re
(D) ATP content in C2C12 cells treated with 25 or 50 mM resveratrol for 1, 4, 6, a
(E) Representative immunoblot for for p-AMPK (Thr172), and total AMPK in C2C
(F) NAD+ content in C2C12 cells treated with 25 or 50 mM resveratrol for 1, 4, 6, an
(G) Representative immunoblot for for p-AMPK (Thr172), and total AMPK in primar
500 mM AICAR for 24 hr.
(H) Mitochondrial DNA content analyzed by quantitative PCR in primary myoblas
AICAR for 24 hr. Relative expression values were normalized to control (n = 3, *p
(I) ATP content in primary myoblasts isolated from wild-type and SIRT1 knockout
(J) C2C12 cells infected with SIRT1 or nontargeting shRNA and expressing Flag-
tested in Flag immunoprecipitates. Total LKB1 was evaluated in total extracts as
(K) Moderate doses of resveratrol activate AMPK and stimulate mitochondria
mitochondrial function.
Values are expressed as mean ±SEM.
CPrimary Myoblast and Hepatocyte Isolation and Treatments
The isolationmethods of primarymyoblasts from the adult-inducible SIRT1 KO
animals and primary hepatocytes from liver-specific SIRT1 KO animals can be
found in the Supplemental Information as well as the cell culture procedures
and treatments.
Mitochondrial Function and Citrate Synthase Activity
Skeletal muscle mitochondria were isolated as described previously (Frezza
et al., 2007), with minor modifications. Oxygen consumption of isolated mito-
chondria was polarographically determined with a Clark oxygen electrode as
described before (Rolo et al., 2000). Mitochondrial membrane potential and
citrate synthase activity was also determined as described previously
(Rolo et al., 2003; Srere et al., 1963). Additional details can be found in the
Supplemental Information. ATP content was measured with a commercial kit
according to the manufacturer’s instructions (Roche). AMP/ATP ratio was
measured by HPLC, and the detailed methods can also be found in the
Supplemental Information.
Immunohistochemical Analysis and Electron Microscopy
Immunohistochemical and electron microscopy methodologies can be found
in the Supplemental Information.
Gene Expression and mtDNA Analysis
Gene expression and mtDNA methodologies can be found in the Supple-
mental Information as well as the primer sequences.
Immunoprecipitation and Immunoblot
Immunoprecipitation and immunoblot methodologies can be found in the
Supplemental Information.
NAD+ Measurement
NAD+ from C2C12 cells and skeletal muscle was quantified with a commer-
cially available kit (BioVision) according to the manufacturer’s instructions
and as described before (Gomes et al., 2012).
Statistical Analysis
Data were analyzed by a two-tailed unpaired Student’s t test. All data are
reported as mean ±SEM. Statistical analysis was performed using Excel
software.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures, two tables, Supplemental
Experimental Procedures, and Supplemental References and can be found
with this article at doi:10.1016/j.cmet.2012.04.003.
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